Kodiak, Merck and Novo Nordisk announce notable biotech advances
Kodiak Sciences reported its vision-preserving drug Zenkuda matched Eylea in a Phase 3 trial, Merck paid $400 million for global rights to a KRAS-targeted cancer candidate from SciBrunch Therapeutics, and Novo Nordisk is positioning its GLP-1 medicines as consumer weight-loss products.
Kodiak Sciences announced that its experimental, vision-sparing therapy Zenkuda demonstrated statistical equivalence to the established anti-VEGF drug Eylea in a Phase 3 clinical trial, suggesting a potential new option for age-related blindness. Merck revealed it has paid $400 million upfront to Chinese biotech SciBrunch Therapeutics for the global license to a preclinical oncology candidate that targets tumors with the KRAS G12D mutation; the agreement could total $2.13 billion if all milestones are met.
In a separate development, Novo Nordisk is increasingly marketing its GLP-1 medicines not only as treatments for chronic disease but also as consumer products aimed at people seeking weight loss, a shift occurring while insurance reimbursement for these obesity drugs remains limited. These moves reflect ongoing innovation and strategic positioning within the biotech sector. The announcements were part of a broader biotech briefing that also included a call to subscribe to a related newsletter. No further details on regulatory status or market launch timelines were provided.
Why it matters
The updates signal new treatment possibilities and market strategies that could affect patients and investors in the biotech field.
In this story
